MRNA - Moderna Stock Is Soaring Today - Here's Why | Benzinga
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection.
The data builds on the Phase 2 trial that showed that after about two years, recurrence of cancer or death was reported in 22% of patients who got the shot and the immunotherapy Keytruda and in 40% ...